Peptides.
What's known. What isn't.
46 profiles. Dose, mechanism, real evidence.
No affiliates. No agenda.
Where to start
Three paths.
One is yours.
FIRST READ Field fundamentals
For anyone arriving for the first time who wants to understand what the evidence says before reading further.
ON PROTOCOL Session reference
For anyone following an active protocol who needs concrete data: reconstitution, dosages, escalation.
RESEARCH Recent literature, verified
For anyone following the field closely who wants the latest with real sources, not third-party summaries.
News
The latest,
with sources.
Retatrutide enters phase 3 with the TRIUMPH program
The design of TRIUMPH was published: four phase 3 trials of the triple GIP/GLP-1/glucagon agonist, with more than 5,800 participants, in weight, sleep apnea and knee osteoarthritis. It is a design paper, not a results paper; phase 3 efficacy is not yet reported.
View source ↗
Thymosin alpha-1 reduces infections and inflammatory markers in severe acute pancreatitis
A 2025 meta-analysis of 5 RCTs (706 patients) found that Tα1 significantly reduced extrapancreatic infections, abdominal infections, and inflammatory markers (CRP, APACHE II). The documented mechanism is immune regulation: Tα1 raised CD4+ counts and restored the CD4+/CD8+ ratio.
Survodutide improves MASH in a phase 2 trial
At 48 weeks, the dual glucagon/GLP-1 agonist resolved MASH without worsening fibrosis in 47 to 62% of the dose groups versus 14% with placebo. It is phase 2, with nausea (66%) and vomiting (41%) common; phase 3 confirmation is still pending.
New profiles and news. No spam.
Research use only. Unsubscribe anytime.
Retatrutide · GLP-3 · Clinical evidence
Retatrutide.
What the trials say.
Direct links to the trials published in NEJM and FDA.
Read the source, not the summary.
When you hear "GLP-3," nobody is talking about a real biological receptor — it doesn't exist. It's the informal name that the press and scientific community use for triple agonists: a new generation of drugs that, unlike traditional medications acting on one or two receptors, stimulates three distinct hormonal receptors simultaneously.
Glucagon-like peptide-1
Reduces appetite and slows gastric emptying.
Glucose-dependent insulinotropic polypeptide
Optimizes insulin secretion and fat metabolism.
Glucagon receptor (GCGR)
The third element: increases energy expenditure and helps the body burn more calories.
Generation comparison
Weight loss: 24.2% at 48 weeks
The triple GLP-1 / GIP / glucagon agonist outperformed every approved peptide to date. 12 mg/week, the largest reduction documented for a metabolic drug.
Read study ↗
MASH resolution in 62% of patients
Reduced liver fat and fibrosis regression at 52 weeks. Measured by MRI-PDFF, the gold standard (tirzepatide).
Read study ↗
Sleep apnea: 25–29 fewer events/hour
40–50% of patients reached full resolution or mild status. FDA approved Zepbound for moderate-to-severe obstructive apnea (tirzepatide).
Read study ↗
Retatrutide Phase 3: up to 28.7% weight loss at 80 weeks
First Phase 3 obesity trial. All doses (4, 9, and 12 mg) met primary and key secondary endpoints. The most recent data available — FDA approval pending.
View release ↗Guide in preparation
Ultimate Guide: Retatrutide
Usage protocol, dose escalation, precision nutrition, side-effect management and the studies behind every recommendation. In English, with real sources.
- Escalation 1 mg → 12 mg: week by week
- Nutritional protocol (protein, leucine, glucose)
- Managing nausea, reflux and constipation
- What the NEJM Phase 2 trial says about the long term
Let me know when it's available. No spam.
Research use only. Not medical advice. You can unsubscribe anytime.
Interactive visualization
The peptide.
The journey.
Select a compound and explore how it activates each target organ. Click the dots to see the mechanism.
Three steps
How to use
the reference.
Locate the peptide in the catalog. FDA status visible from the first card.
Mechanism, reported dosages, side effects, and clinical evidence with sources.
The calculator converts vial mg + water ml into U-100 units. No math required.
Our approach
The reference that treats you like a
researcher.
We don't sell. We don't diagnose. We don't simplify down.
Every profile is structured research, with real sources.
Most asked
No fine print.
01 Do you sell peptides?
No. We have no store and no affiliates. If the information is clear, it's because we have nothing to sell you.
02 Is this medical advice?
No. This is educational material, research use only. We don't prescribe doses: every decision about your body goes through a licensed professional.
03 How is this different from a forum or Reddit?
We work from peer-reviewed sources and FDA status, and always separate human data from animal or anecdotal findings. Anecdote is not evidence.
04 Does tirzepatide improve fatty liver?
Yes. The SYNERGY-NASH trial (NEJM 2024) showed MASH resolution in 62% of participants with tirzepatide, vs. 19% with placebo. The effect comes both from weight reduction and directly from hepatic lipid metabolism.